High expression of TIGIT is predictive of tumor progression in multiple myeloma and is associated with poor outcomes and resistance to PD-1 immune checkpoint inhibitors in follicular lymphoma [15]. This evidence concerns the gene TIGIT and plasma cell myeloma.